Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Operating Leases (2020 - 2025)

BridgeBio Pharma's Operating Leases history spans 6 years, with the latest figure at $10.0 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 113.01% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, up 113.01%, while the annual FY2025 figure was $10.0 million, 113.01% up from the prior year.
  • Operating Leases for Q4 2025 was $10.0 million at BridgeBio Pharma, up from $3.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $18.7 million in Q3 2021 and bottomed at $3.4 million in Q3 2025.
  • The 5-year median for Operating Leases is $10.5 million (2023), against an average of $10.6 million.
  • The largest annual shift saw Operating Leases surged 126.85% in 2021 before it crashed 47.71% in 2024.
  • A 5-year view of Operating Leases shows it stood at $17.4 million in 2021, then fell by 29.57% to $12.3 million in 2022, then fell by 26.83% to $9.0 million in 2023, then crashed by 47.71% to $4.7 million in 2024, then soared by 113.01% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Operating Leases are $10.0 million (Q4 2025), $3.4 million (Q3 2025), and $4.0 million (Q2 2025).